Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis

Journal of Neuroimmunology

Volumn 203, Issue 1, 2008, Pages 94-103

  Cudrici, Cornelia ^a   Ito, Takahiro ^a   Zafranskaia, Ekaterina ^a   Weerth, Susanna ^b   Rus, Violeta ^a   Chen, Hegang ^a   Niculescu, Florin ^a   Soloviova, Katerina ^a   Tegla, Cosmin ^a   Gherman, Adrian ^a   Raine, Cedric S ^b   Shin, Moon L ^a   Rus, Horea ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

C5b 9; Complement; Connective tissue growth factor; Experimental allergic encephalomyelitis; Insulin like growth factor binding proteins

Indexed keywords

COMPLEMENT COMPONENT C5; CONNECTIVE TISSUE GROWTH FACTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; TRANSFORMING GROWTH FACTOR BETA3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; TISSUE REPAIR;

ANIMALS; ANIMALS, OUTBRED STRAINS; BLOTTING, WESTERN; CHRONIC DISEASE; COMPLEMENT C5; CONNECTIVE TISSUE GROWTH FACTOR; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIOSIS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MICE; MICE, CONGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD;

EID: 53149145652     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.06.040     Document Type: Article

References (47)

1. Abreu J.G., Ketpura N.I., Reversade B., and De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4 (2002) 599-604
2. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., Harris M.A., Hill D.P., Issel-Tarver L., Kasarskis A., Lewis S., Matese J.C., Richardson J.E., Ringwald M., Rubin G.M., and Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (2000) 25-29
3. Beilharz E.J., Russo V.C., Butler G., Baker N.L., Connor B., Sirimanne E.S., Dragunow M., Werther G.A., Gluckman P.D., Williams C.E., and Scheepens A. Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res. Mol. Brain Res. 59 (1998) 119-134
4. Boers W., Aarrass S., Linthorst C., Pinzani M., Elferink R.O., and Bosma P. Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J. Biol. Chem. 281 (2006) 16289-16295
5. Brigstock D.R. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr. Rev. 20 (1999) 189-206
6. Carney D.F., Koski C.L., and Shin M.L. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J. Immunol. 134 (1985) 1804-1809
7. Carson M.J., Behringer R.R., Brinster R.L., and McMorris F.A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10 (1993) 729-740
8. Chesik D., De Keyser J., Glazenburg L., and Wilczak N. Insulin-like growth factor binding proteins: regulation in chronic active plaques in multiple sclerosis and functional analysis of glial cells. Eur. J. Neurosci. 24 (2006) 1645-1652
9. Chesik D., Wilczak N., and De Keyser J. The insulin-like growth factor system in multiple sclerosis. Int. Rev. Neurobiol. 79 (2007) 203-226
10. Conrad S., Schluesener H.J., Adibzahdeh M., and Schwab J.M. Spinal cord injury induction of lesional expression of profibrotic and angiogenic connective tissue growth factor confined to reactive astrocytes, invading fibroblasts and endothelial cells. J. Neurosurg. Spine 2 (2005) 319-326
11. Cragg M.S., Howatt W.J., Bloodworth L., Anderson V.A., Morgan B.P., and Glennie M.J. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ. 7 (2000) 48-58
12. Cudrici C., Niculescu F., Jensen T., Zafranskaia E., Fosbrink M., Rus V., Shin M.L., and Rus H. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J. Immunol. 176 (2006) 3173-3180
13. Cudrici C., Summers D., Jansen T., Fosbrink M., and Rus H. C5b-9 protects oligodendrocytes apoptosis by regulating BH-3-only proapoptotic proteins. FASEB J. 19 (2005) A324
14. Frazier K., Williams S., Kothapalli D., Klapper H., and Grotendorst G.R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J. Invest. Dermatol. 107 (1996) 404-411
15. Gentleman R.C., V.J., Huber W., Irizarry R.A., and Dudoit S. Bioinformatics and Computational Biology Solutions using R and Bioconductor (2005), Springer, New York
16. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8 (1997) 171-179
17. Halperin J.A., Taratuska A., and Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J. Clin. Invest. 91 (1993) 1974-1978
18. Hamada Y., Ikata T., Katoh S., Katoh K., Niwa M., Tsutsumishita Y., and Fukuzawa K. Effects of exogenous transforming growth factor-beta 1 on spinal cord injury in rats. Neurosci. Lett. 203 (1996) 97-100
19. Holley J.E., Gveric D., Newcombe J., Cuzner M.L., and Gutowski N.J. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol. Appl. Neurobiol. 29 (2003) 434-444
20. Holly J., and Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 83 (2006) 154-160
21. Hosack D.A., Dennis Jr. G., Sherman B.T., Lane H.C., and Lempicki R.A. Identifying biological themes within lists of genes with EASE. Genome Biol. 4 (2003) R70
22. Koski C.L., Estep A.E., Sawant-Mane S., Shin M.L., Highbarger L., and Hansch G.M. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J. Neurochem. 66 (1996) 303-312
23. Kothapalli D., Frazier K.S., Welply A., Segarini P.R., and Grotendorst G.R. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ. 8 (1997) 61-68
24. Kuhl N.M., De Keyser J., De Vries H., and Hoekstra D. Insulin-like growth factor binding proteins-1 and -2 differentially inhibit rat oligodendrocyte precursor cell survival and differentiation in vitro. J. Neurosci. Res. 69 (2002) 207-216
25. Liu W.T., Vanguri P., and Shin M.L. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J. Immunol. 131 (1983) 778-782
26. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(- Delta Delta C(T)) method. Methods 25 (2001) 402-408
27. Logan A., and Berry M. Transforming growth factor-beta 1 and basic fibroblast growth factor in the injured CNS. Trends Pharmacol. Sci. 14 (1993) 337-342
28. Lovett-Racke A.E., Bittner P., Cross A.H., Carlino J.A., and Racke M.K. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J. Clin. Invest. 101 (1998) 1797-1804
29. Mead R.J., Singhrao S.K., Neal J.W., Lassmann H., and Morgan B.P. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 168 (2002) 458-465
30. Morgan B.P., Griffiths M., Khanom H., Taylor S.M., and Neal J.W. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clin. Exp. Immunol. 138 (2004) 430-438
31. Niculescu F., Rus H., van Biesen T., and Shin M.L. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158 (1997) 4405-4412
32. Niculescu T., Weerth S., Niculescu F., Cudrici C., Rus V., Raine C.S., Shin M.L., and Rus H. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J. Immunol. 172 (2004) 5702-5706
33. Papadimitriou J.C., Ramm L.E., Drachenberg C.B., Trump B.F., and Shin M.L. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J. Immunol. 147 (1991) 212-217
34. Papadimitriou J.C., Drachenberg C.B., Shin M.L., and Trump B.F. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch. 424 (1994) 677-685
35. Pilewski J.M., Liu L., Henry A.C., Knauer A.V., and Feghali-Bostwick C.A. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am. J. Pathol. 166 (2005) 399-407
36. Reiman R., Gerard C., Campbell I.L., and Barnum S.R. Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur. J. Immunol. 32 (2002) 1157-1163
37. Rus H., and Niculescu F. The complement system in central nervous system diseases. Immunol. Res. 24 (2001) 79-86
38. Rus H.G., Niculescu F., and Shin M.L. Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156 (1996) 4892-4900
39. Rus H., Niculescu F., Badea T., and Shin M.L. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway. Immunopharmacology 38 (1997) 177-187
40. Scolding N.J., Morgan B.P., Houston W.A., Linington C., Campbell A.K., and Compston D.A. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339 (1989) 620-622
41. Shirazi Y., Imagawa D.K., and Shin M.L. Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J. Neurochem. 48 (1987) 271-278
42. Soane L., Rus H., Niculescu F., and Shin M.L. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 163 (1999) 6132-6138
43. Soane L., Cho H.J., Niculescu F., Rus H., and Shin M.L. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J. Immunol. 167 (2001) 2305-2311
44. Vanguri P., and Shin M.L. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. J. Biol. Chem. 263 (1988) 7228-7234
45. Weerth S.H., Rus H., Shin M.L., and Raine C.S. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am. J. Pathol. 163 (2003) 1069-1080
46. Wu Z., Irizarry R.A., Gentleman R., Martinez-Murillo F., and Spencer F. A model-based background adjustment for oligonucleotide expression arrays. JASA 99 (2004) 909-917
47. Yasuoka H., Jukic D.M., Zhou Z., Choi A.M.K., and Feghali-Bostwick C.A. Insulin-like growth factor binding protein 5 induces skin fibrosis: a novel murine model for dermal fibrosis. Arthritis rheum. 54 (2006) 3001-3010